← back to search

Tobias Förster

Ludwig-Maximilians-Universität München · DE
Area of research
Cancer Research · Radiation
Research interest
Research interests include Medicine, Radiation therapy, Breast cancer, Common Terminology Criteria for Adverse Events, Internal medicine, and Nuclear medicine.
h-index
citations
523
works
27
NIH funding
primary concept
email

Recent publications

Incidence and Risk Assessment of Capsular Contracture in Breast Cancer Patients following Post-Mastectomy Radiotherapy and Implant-Based Reconstruction
Cancers 2024cited by 21position: middledoi
Bone Marrow Sparing by Intensity Modulated Proton Beam Therapy in Postoperative Irradiation of Gynecologic Malignancies
Technology in Cancer Research & Treatment 2024cited by 10position: middledoi
Palliative Radiotherapy for Symptomatic Locally Advanced Breast Cancer
Technology in Cancer Research & Treatment 2023cited by 15position: middledoi
Treatment Tolerability and Toxicity of Postoperative Proton Beam Therapy for Gynecologic Malignancies: Results of the Prospective Phase 2 APROVE Trial
International Journal of Radiation Oncology*Biology*Physics 2023cited by 13position: middledoi
Health-related quality of life and patient-reported symptoms after postoperative proton beam radiotherapy of cervical and endometrial cancer: 2-year results of the prospective phase II APROVE-trial
Radiation Oncology 2023cited by 12position: middledoi
Noninferiority of Local Control and Comparable Toxicity of Intensity Modulated Radiation Therapy With Simultaneous Integrated Boost in Breast Cancer: 5-Year Results of the IMRT-MC2 Phase III Trial
International Journal of Radiation Oncology*Biology*Physics 2023cited by 9position: firstdoi
Dosimetric Benefit of Adaptive Magnetic Resonance-Guided Stereotactic Body Radiotherapy of Liver Metastases
Cancers 2022cited by 23position: middledoi
Stereotactic magnetic resonance-guided online adaptive radiotherapy of adrenal metastases combines high ablative doses with optimized sparing of organs at risk
Clinical and Translational Radiation Oncology 2022cited by 16position: middledoi
Methods of Esthetic Assessment after Adjuvant Whole-Breast Radiotherapy in Breast Cancer Patients: Evaluation of the BCCT.core Software and Patients’ and Physicians’ Assessment from the Randomized IMRT-MC2 Trial
Cancers 2022cited by 4position: firstdoi
Effect of timing, technique and molecular features on brain control with local therapies in oncogene-driven lung cancer
ESMO Open 2021cited by 17position: middledoi
Quality of life after simultaneously integrated boost with intensity-modulated versus conventional radiotherapy with sequential boost for adjuvant treatment of breast cancer: 2-year results of the multicenter randomized IMRT-MC2 trial
Radiotherapy and Oncology 2021cited by 17position: firstdoi
Intensity Modulated Radiation Therapy (IMRT) With Simultaneously Integrated Boost Shortens Treatment Time and Is Noninferior to Conventional Radiation Therapy Followed by Sequential Boost in Adjuvant Breast Cancer Treatment: Results of a Large Randomized Phase III Trial (IMRT-MC2 Trial)
International Journal of Radiation Oncology*Biology*Physics 2020cited by 59position: middledoi
Extracranial Stereotactic Body Radiotherapy in Oligometastatic or Oligoprogressive Breast Cancer
Frontiers in Oncology 2020cited by 36position: middledoi
Single-Isocenter Volumetric Modulated Arc Therapy vs. CyberKnife M6 for the Stereotactic Radiosurgery of Multiple Brain Metastases
Frontiers in Oncology 2020cited by 30position: middledoi
Accelerated Partial Breast Irradiation: A New Standard of Care?
Breast Care 2020cited by 20position: firstdoi
Stereotactic Cavity Irradiation or Whole-Brain Radiotherapy Following Brain Metastases Resection—Outcome, Prognostic Factors, and Recurrence Patterns
Frontiers in Oncology 2020cited by 18position: middledoi
Acute toxicity of normofractionated intensity modulated radiotherapy with simultaneous integrated boost compared to three-dimensional conformal radiotherapy with sequential boost in the adjuvant treatment of breast cancer
Radiation Oncology 2020cited by 17position: middledoi
A matched-pair analysis comparing stereotactic radiosurgery with whole-brain radiotherapy for patients with multiple brain metastases
Journal of Neuro-Oncology 2020cited by 16position: middledoi
Fatigue following radiotherapy of low-risk early breast cancer – a randomized controlled trial of intraoperative electron radiotherapy versus standard hypofractionated whole-breast radiotherapy: the COSMOPOLITAN trial (NCT03838419)
Radiation Oncology 2020cited by 11position: firstdoi
Adjuvant Radiation Therapy for Male Breast Cancer—A Rare Indication?
Cancers 2020cited by 6position: firstdoi
Validation of Nine Different Prognostic Grading Indexes for Radiosurgery of Brain Metastases in Breast Cancer Patients and Development of an All-Encompassing Prognostic Tool
Frontiers in Oncology 2020cited by 6position: middledoi
Treatment Outcome of 227 Patients with Sinonasal Adenoid Cystic Carcinoma (ACC) after Intensity Modulated Radiotherapy and Active Raster-Scanning Carbon Ion Boost: A 10-Year Single-Center Experience
Cancers 2019cited by 33position: middledoi
Bimodal Radiotherapy with Active Raster-Scanning Carbon Ion Radiotherapy and Intensity-Modulated Radiotherapy in High-Risk Nasopharyngeal Carcinoma Results in Excellent Local Control
Cancers 2019cited by 26position: middledoi
Second breast conserving therapy after ipsilateral breast tumor recurrence – a 10-year experience of re-irradiation
Journal of Contemporary Brachytherapy 2019cited by 16position: firstdoi
The impact of age on the outcome of patients treated with radiotherapy for mucoepidermoid carcinoma (MEC) of the salivary glands in the head and neck: A 15-year single-center experience
Oral Oncology 2019cited by 15position: middledoi
Treatment Outcome of a Combined Dose-Escalated Treatment Regime With Helical TomoTherapy® and Active Raster-Scanning Carbon Ion Boost for Adenocarcinomas of the Head and Neck
Frontiers in Oncology 2019cited by 4position: middledoi
Sulforaphane counteracts aggressiveness of pancreatic cancer driven by dysregulated Cx43-mediated gap junctional intercellular communication
Oncotarget 2014cited by 53position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

Jürgen Debus · NYU Langone Health26 papers (2019–2024)Laila König · Heidelberg University19 papers (2019–2024)Juliane Hörner‐Rieber · German Cancer Research Center17 papers (2019–2024)Nathalie Arians · Heidelberg University14 papers (2019–2024)Kristin Lang · Heidelberg University13 papers (2019–2024)Fabian Weykamp · German Cancer Research Center10 papers (2020–2023)Eva Meixner · DKFZ-ZMBH Alliance9 papers (2021–2024)Sebastian Adeberg · Goethe University Frankfurt8 papers (2019–2020)Stefan Rieken · University Medical Center7 papers (2019–2021)Andreas Schneeweiß · NSABP Foundation7 papers (2019–2023)Rami A. El Shafie · University Medical Center7 papers (2019–2021)Sati Akbaba · German Cancer Research Center7 papers (2019–2020)David Krug · University Hospital Heidelberg7 papers (2019–2023)Klaus Herfarth · Universitätsklinik für Strahlentherapie7 papers (2019–2024)Christof Sohn · University Hospital Heidelberg6 papers (2019–2021)Philipp Hoegen · German Cancer Research Center6 papers (2020–2024)Semi Harrabi · Heidelberg University6 papers (2020–2023)Matthias Häfner · University Hospital Heidelberg6 papers (2019–2023)Clara Köhler · University Hospital Heidelberg6 papers (2020–2024)Ingmar Schlampp · University Hospital Heidelberg5 papers (2020–2023)